COVID-19 Research and Development: Four Major Pharmaceutical Companies Announced The Latest Today

Genetek teamed up with Gilead Scienceto to launch Phase 3 clinical trials to test the combination therapy of Redsiewe/IL-6 inhibitors
Roche announced today that it will work with Gilead Sciences to launch a randomized double-blind, global Phase 3 clinical trial to test its IL-6 monoclonal antibody Actemra (tocilizumab) for the treatment of the antiviral drug RedcieAs the study of COVID-19 progressed, scientists realized that the cause of exacerbation of the condition in patients with neo-coronary pneumonia was not only damage to tissues caused by viral infections, but also inflammatory damage caused by the body's excessive immune responseRecently, Redsyway was validated in Phase 3 clinical trials to improve recovery in patients with severe new coronary pneumoniaSo, can this antiviral therapy and the drug that suppresses the inflammatory response lead to better treatment?Genentech has launched a Phase 3 clinical trial to test the safety and efficacy of Actemra's treatment of patients hospitalized with severe new coronary pneumoniaIL-6 plays a key role in cytokine storms in patients with co-mediated neo-coronary pneumoniaActemra is an anti-IL-6 monoclonal antibody that has been approved to treat rheumatoid arthritisGenentech said phase 3 clinical trials to test Actemra's monodotherapy have been registered and are expected to be available this summerPhase 3 clinical trial of the test combination therapy is expected to enroll 450 patients and will begin to register patients in Junebased on the same scenario, the U.SNational Institute of Allergy and Infectious Diseases (NIAID) has also launched clinical trials to study the safety and efficacy of patients with severe neoprene pneumonia, a combination of redsiewe and JAK inhibitor OluminantNovartis and Professor James Wilson, a pioneer in gene therapy, joined the new coronavaccine development program
the University of Pennsylvania announced today that the Department of Gene Therapy, led by renowned gene therapy pioneer Professor James Wilson, will join a vaccine development project led by researchers at Massachusetts Eye and Ear Hospital and Massachusetts General HospitalThe vaccine development project, called AAVCOVID, aims to develop adeno-related virus (AAV) vectors that express the new coronavirus gene as a vaccine against neo-coronavirus infectionAAV is a commonly used viral vector in a variety of gene therapies, and Professor Wilson has deep experience in developing and optimizing AAV vectorsDr Luk Vandenberghe, the lead author of the AAVCOVID program, was a Doctoral Student in Professor Wilson's Laboratory While studying in Professor Wilson's lab, he designed an AAV vector that stimulates the body's immune response The expression of the new coronavirus gene with this AAV vector is expected to stimulate a strong human immune response At the same time, the safety of AAV vectors has been validated in clinical trials of several gene therapies at the same time, AveXis, a gene therapy company owned by Novartis, announced its participation in the vaccine development Novartis' approved gene therapy For Spinal Muscular Dystrophy (SMA), Zolgensma, was developed and produced by AveXis This is a gene therapy based on aAV vector AveXis announced that it will use its expertise and production capacity in gene therapy to produce the candidate vaccine free of charge to support clinical trials to be conducted later this year "The first question that often needs to be answered for new crown vaccine development projects is - how can this vaccine expand production?" Dr Vandenberghe said: "AveXis has mass-produced Gene therapy products based on AAV vectors Working with the company will help us reach our goal of sending vaccines globally to prevent new coronavirus infections "GlaxoSmithKline, plans to produce 1 billion doses of adjozolitos to support global partner vaccine development
GlaxoSmithKline (GSK) announced today that it plans to produce 1 billion doses of pandemic vaccine adjovaccine (adjuvant) system by 2021 to support the development of a number of new crown virus candidate vaccines using a dj GSK believes that its adjuno technology can make a significant contribution to the capture of COVID-19 The adjuas reduce the amount of viral protein in each dose of the vaccine, thus producing more doses of the vaccine and protecting more people Moreover, adjfrom the body's immune response can help stimulate a stronger and longer-lasting immune response GSK has entered into research and development agreements with Sanofi, the University of Queensland and Shamrock Biopharma to provide adjother to support the development of the new crown vaccine for these institutions "We believe that we need more than one vaccine to overcome this global pandemic," said Roger Connor, global president of GSK That's why we work with our global partners to support efforts to combat COVID-19 References: S Gene Therapy Program at Penn Joins AAVCOVID Vaccine Project Retrieved May 28, 2020, from https:// 2? COVID-19 Vaccine, AAVCOVID Biotech Retrieved May 28, 2020, from https://masseyeandear.org/covid-19/vaccine 3, Novartis jumps into Covid-19 vaccine hunt hunt, as Big Pharma and big big commit to billions of the stos Retrieved May 28, 2020, from https://endpts.com/novartis-jumps-into-covid-19-vaccine-hunt-as-big-pharma-and-big-biotech-commit-to-billions-of-doses/ 4 s gSK announces intention to produce 1 billion doses of vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations Retrieved May 28, 2020, from https:// 5 s Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Rraed Patients With COVID-19 Pneumonia Retrieved May 28, 2020, https:// (original title: COVID-19 Research and Development: What's new from Roche, Gilead Science, Novartis, GlaxoSmithKline?) )